Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2023, 167(3):236-245 | DOI: 10.5507/bp.2022.010

Infectious complications of induction treatment for acute myeloid leukaemia using the "7 + 3" protocol without antibiotic prophylaxis - 15 years of experience of one clinical site

Martin Cernan1, Tomas Szotkowski1, Jaromir Hubacek1, Milan Kolar2, Edgar Faber1, Karel Indrak1, Tomas Papajik1
1 Department of Haemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, I. P. Pavlova 6, 779 00 Olomouc, Czech Republic
2 Department of Microbiology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, I. P. Pavlova 6, 779 00 Olomouc, Czech Republic

Background: Infectious complications during induction chemotherapy of acute myeloid leukaemia are very common. Prophylactic use of antibiotics however is an ongoing challenge in this situation due to bacterial multi-drug resistance. The aim of this study was to provide a comprehensive overview of the incidence of infectious complications in patients with AML undergoing induction therapy using the "7+3" protocol without routine antibiotic prophylaxis at one clinical site providing specialised haematological care in the Czech Republic, over a period of 15 years. The study also evaluates the aetiological spectrum of causative agents and the development of antibiotic resistance in the context of the use of the various classes of antibiotics. The analysis includes evaluation of the importance of risk factors for infectious complications and their impact on treatment of the underlying disease. The data are compared with published figures for similar cohorts of patients.

Patients and Methods: This study presents a retrospective analysis of infectious complications in 242 patients with acute myeloid leukaemia undergoing the first cycle of induction therapy without routine antibiotic prophylaxis in one clinical site in Czech Republic during years 2006-2020.

Results: A total of 363 febrile episodes (FE) were recorded. At least 1 FE during the induction was detected in 229 (94.6%) patients. Clinically defined infection was the cause in 96 (26.4%) FEs and blood stream infection in 69 (19.0%) FEs. Both complications occurred simultaneously in 29 (8.0%) FEs. 169 (46.6%) FEs were evaluated as fever of unknown origin (FUO). The achievement of complete remission had a significant effect on the duration of the FE (6 vs. 9 days, P=0.0005) and on the overall survival duration (79.3 vs. 6.5 months, P<0.0001). Patients diagnosed with infection or FUO at diagnosis were significantly more likely to suffer from colonisation by multi-drug resistant bacterial strains at discharge (29.2% vs. 16.3%, P=0.022). This group of patients used antibiotic therapy for a significantly longer time (35 vs. 23 days, P<0.0001). Infection was a contributing cause of death in 18 (7.4%) patients. Mortality was significantly related to the failure to achieve complete remission (P<0.0001).

Conclusion: Infectious mortality during induction treatment without routine antibiotic prophylaxis was comparable to the published cohorts with prophylaxis. Regular microbiology surveillance with adequate initial antibiotic treatment can compensate routine antibiotic prophylaxis with slower development of antibiotic resistance.

Keywords: acute myeloid leukaemia, induction therapy, infectious complications, antibiotic prophylaxis, antibiotic resistance, mortality

Received: November 13, 2021; Revised: February 14, 2022; Accepted: February 15, 2022; Prepublished online: March 1, 2022; Published: September 21, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Cernan, M., Szotkowski, T., Hubacek, J., Kolar, M., Faber, E., Indrak, K., & Papajik, T. (2023). Infectious complications of induction treatment for acute myeloid leukaemia using the "7 + 3" protocol without antibiotic prophylaxis - 15 years of experience of one clinical site. Biomedical papers, 167(3), 236-245. doi: 10.5507/bp.2022.010
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer Journal 2016;6:e441. Go to original source...
    2. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64(2):328-40. Go to original source...
    3. Giamarellou H , Antoniadou A. Infectious complications of febrile leukopenia. Infect Dis Clin North Am 2001;15(2):457-82. Go to original source... Go to PubMed...
    4. Bent-Are Hansen BA, Wendelbo Ø, Bruserud Ø, Hemsing AL, Mosevoll KA, Reikvam H. Febrile Neutropenia in Acute Leukemia. Epidemiology, Etiology, Pathophysiology and Treatment. Mediterr J Hematol Infect Dis 2020;12(1):e2020009. Go to original source... Go to PubMed...
    5. Othus M, Kantarjian H, Petersdorf S, Ravandi F, Godwin J, Cortes J, Pierce S, Erba H, Faderl S, Appelbaum FR, Estey E. Declining Rates of Treatment-Related Mortality in Patients with Newly-diagnosed AML Given "Intense" Induction Regimens: A Report from SWOG and MD Anderson. Leukemia 2014;28(2):289-92. Go to original source...
    6. Philip C, George B, Ganapule A, Korula A, Jain P, Alex AA, Lakshmi KM, Sitaram, Abubacker FN, Abraham A, Viswabandya A, Srivastava VM, Srivastava A, Balasubramanian P, Mathews W. Acute myeloid leukaemia: challenges and real world data from India. Br J Haematol 2015;170(1):110-17. Go to original source...
    7. Pandian J, Raghavan V, Manuprasad A, Shenoy PK, Nair CK. Infection at diagnosis-a unique challenge in acute myeloid leukemia treatment in developing world. Support Care Cancer 2020;28(11):5449-54. Go to original source... Go to PubMed...
    8. Kayal S, Sengar M, Jain H, Bonda A, George B, Kulkarni UP, Balasubramanian P, Bhurani D, Ahmed R, Biswajit D, Jayachandran PK, Batra A, Kumar S, Mishra K, Bhattacharyya J, Philip CC, Bhattacharyya M, Dasappa L, Babu KG, Saldanha SC, Sharma A, Lakshmanan J, Durairaj J, Rudravaram VV, Mathews W, Kapoor R. Induction Related Mortality in Acute Myeloid Leukemia: Multivariate Model of Predictive Score from the Indian Acute Leukemia Research Database (INwARD) of the Hematology Cancer Consortium (HCC). Blood (2019);134 (S1):2615. Go to original source...
    9. Van Boeckel TP, Gandra S, Ashok A, Caudron Q, Grenfell BT, Levin SA, Laxminarayan R. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect Dis 2014;14(8):742-50. Go to original source... Go to PubMed...
    10. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine LR, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, Löwenberg B, Bloomfield CD. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood (2017);129(4):424-47. Go to original source...
    11. Garcia-Horton A, Yee KW. Quizartinib for the treatment of acute myeloid leukemia. Expert Opin Pharmacother 2020;21(17):2077-90. Go to original source... Go to PubMed...
    12. Donnelly JP , Chen CC , Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, Clancy CJ, Wingard JR, Lockhart SR, Groll AH, Sorrell TC, Bassetti M, Akan H, Alexander BD, Andes D, Azoulay E, Bialek R, Bradsher RW, Bretagne S, Calandra T, Caliendo AM, Castagnola E, Cruciani M, Cuenca-Estrella M, Decker CF, Desai SR, Fisher B, Harrison T, Heussel CP, Jensen HE, Kibbler CC, Kontoyiannis PD, Kullberg BJ, Lagrou K, Lamoth F, Lehrnbecher T, Loeffler K, Lortholary O, Maertens K, Marchetti O, Marr KA, Masur K, Meis JF, Morrisey CO, Nucci M, Ostrosky-Zeichner L, Pagano L, Patterson TF, Perfect JR, Racil Z, Roilides E, Ruhnke M, Prokop CS, Shoham S, Slavin MA, Stevens DA, Thompson GR, Vazquez JA, Viscoli C, Walsh TJ, Warris A, Wheat LJ, White PL, Zaoutis TE, Pappas PG. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis 2020;71(6):1367-76. Go to original source...
    13. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falaga ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistence. Clin Microbiol Infect 2012;18:268-81. Go to original source...
    14. Cannas G, Pautas C, Raffoux E, Quesnel B, De Botton S, De Revel T, Reman O, Gardin C, Elhamri M, Boissel N, Fenaux P, Michallet M, Castaigne S, Dombret H, Thomas X. Infectious complications in adult acute myeloid leukemia: analysis of the Acute Leukemia French Association-9802 prospective multicenter clinical trial. Leuk Lymphoma 2012;53(6):1068-76. Go to original source...
    15. Lambert J, Pautas C , Terré Ch , Raffoux E, Turlure P, Caillot D, Legrand O, Thomas X, Gardin C, Gogat-Marchant K, Rubin SD, Benner RJ, Bousset P, Preudhomme C, Chevret C, Dombret H, Castaigne S. Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. Haematologica 2019;104(1):113-19. Go to original source... Go to PubMed...
    16. Aldoss I, Pullarkat V, Stein AS. Venetoclax-containing regimens in acute myeloid leukemia. Ther Adv Hematol 2021;12:2040620720986646. Go to original source...
    17. Buckley SA, Othus M, Vainstein V, Abkowitz JL, Estey EH, Walter RB. Prediction of adverse events during intensive induction chemotherapy for acute myeloid leukemia or high-grade myelodysplastic syndromes. Am J Hematol 2014;89(4):423-28. Go to original source... Go to PubMed...
    18. Pagano L, Caira M, Nosari A, Rossi G, Viale P, Aversa F, Tumbarello M, Hema e-Chart Group, Italy. Etiology of febrile episodes in patients with acute myeloid leukemia: results from the Hema e-Chart Registry. Arch Intern Med 2011;171(16):1502-03. Go to original source...
    19. Lech-Maranda E , Seweryn M, Giebel S, Holowiecki J, Piatkowska-Jakubas B, Piatkowska-Jakubas B, Wegrzyn J, Skotnicki A, Kielbinski M, Kuliczkowski K, Paluszewska M, Jedrzejczak WW, Dutka M, Hellmann A, Flont M, Zdziarska B, Palynyczko G, Konopka L, Szpila T, Gawronski K, Sulek K, Sokolowski J, Kloczko J, Warzocha K, Robak T. Infectious complications in patients with acute myeloid leukemia treated according to the protocol with daunorubicin and cytarabine with or without addition of cladribine. A multicenter study by the Polish Adult Leukemia Group (PALG). Int J Infect Dis 2010;14(2):132-40. Go to original source...
    20. Garcia JB, Lei X, Wierda W, Cortes JE, Dickey BF, Evans SE, Ost DE. Pneumonia during remission induction chemotherapy in patients with acute leukemia. Ann Am Thorac Soc 2013;10(5):432-40. Go to original source...
    21. Syrjälä H, Ohtonen P, Kinnunen U, Räty R, Elonen E, Nousiainen T, Jantunen E, Remes K, Itälä-Remes M, Silvennoinen R, Koistinen P, Finnish Leukemia Group. Blood stream infections during chemotherapy-induced neutropenia in adult patients with acute myeloid leukemia: treatment cycle matters. Eur J Clin Microbiol Infect Dis 2010;29(10):1211-18. Go to original source...
    22. De Rosa FG, Motta I, Audisio E, Frairia Ch., Busca A, Di Perri G, Marmont F. Epidemiology of bloodstream infections in patients with acute myeloid leukemia undergoing levofloxacin prophylaxis. BMC Infect Dis 2013;13:563. Go to original source...
    23. Malagola M, Peli A, Damiani D, Candoni A, Tiribelli M, Martinelli G, Piccaluga PP, Paolini S, De Rosa F, Lauria F, Bocchia M, Gobbi M, Pierri I, Zaccaria A, Zuffa E, Mazza P, Priccolo G, Gugliotta L, Bonini A, Visani G, Skert C, Bergonzi C, Roccaro AM, Filì C, Fanin R, Baccarani M, Russo D. Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases. Eur J Haematol 2008;81(5):354-63. Go to original source...
    24. Weinbergerová B, Kabut T, Kocmanová I, Drgoňa L, Kouba M, Hričinová M, Gabzdilová J, Guman T, Petečuková V, Novák J, Forsterová K, Haber J, Žiaková B, Bojtárová E, Zavřelová A, Karas M, Chrenková V, Sedláček P, Tkáčiková B, Múdry P, Mallátová N, Timr P, Kolenová A, Tanušková D, Horáková J, Navrátil M, Chudej J, Sokol J, Rolencová M, Žák P, Cetkovský P, Mayer J, Ráčil Z. Změny v epidemiologii invazivních mykotických infekcí v českých a slovenských hematoonkologických centrech v letech 2005-2017: analýza dat FIND. Transfuze Hematol. Dnes 2019;2:186-96. [article in Czech]
    25. Heisel RW, Sutton RR , Mascara GP, Winger GD, Weber DR, Lim SH, Oleksiuk LM . Vancomycin-resistant enterococci in acute myeloid leukemia and myelodysplastic syndrome patients undergoing induction chemotherapy with idarubicin and cytarabine. Leuk Lymphoma 2017;58(11):2565-72. Go to original source...
    26. Hricová K , Štosová T, Kučová P, Fišerová K , Bardoň J, Kolář M. Analysis of Vancomycin-Resistant Enterococci in Hemato-Oncological Patients. Antibiotics (Basel) 2020; 9(11):785. Go to original source...
    27. Ballo O, Tarazzit I, Stratmann J, Reinheimer C, Hogardt M, Wichelhaus TA, Kempf V, Serve H, Finkelmeier F, Brandts C. Colonization with multidrug resistant organisms determines the clinical course of patients with acute myeloid leukemia undergoing intensive induction chemotherapy. PLoS One 2019;14(1):e0210991. Go to original source... Go to PubMed...
    28. Kato H, Fujita H, Akiyama N, Kimura SI, Hiramoto N, Hosono N, Takahashi T, Shigeno K, Minamiguchi H, Miyatake J, Handa H, Kanda Y, Yoshida M, Miyawaki S, Ohtake S, Naoe T, Kiyoi H, Matsumura I, Miyazaki Y. Infectious complications in adults undergoing intensive chemotherapy for acute myeloid leukemia in 2001-2005 using the Japan Adult Leukemia Study Group AML201 protocols. Support Care Cancer 2018;26(12):4187-98. Go to original source... Go to PubMed...
    29. Owattanapanich W, Chayakulkeeree M. Efficacy of levofloxacin as an antibacterial prophylaxis for acute leukemia patients receiving intensive chemotherapy: a systematic review and meta-analysis. Hematology 2019;24(1):362-68. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content